

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-69. **(canceled)**

70. **(currently amended)** A method for treating glomerulonephritis in a mammal who is otherwise free of indications for treatment with IFN-β, said indications selected from the group consisting of lupus or viral disease, comprising identifying a mammal having glomerulonephritis and administering to the mammal a therapeutically effective amount of an IFN-β therapeutic.

71. **(original)** The method of claim 70, wherein glomerulonephritis is selected from the group consisting of focal glomerulosclerosis, collapsing glomerulopathies, minimal change disease, crescentic glomerulonephritis, nephritic syndrome, nephrotic syndrome, primary glomerulonephritis, secondary glomerulonephritis, proliferative glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, immune-complex glomerulonephritis, anti-glomerular basement membrane (anti-GBM) glomerulonephritis, pauci-immune glomerulonephritis, diabetic glomerulopathy, chronic glomerulonephritis, and hereditary nephritis.

72. **(previously presented)** The method of claim 70, wherein the IFN-β therapeutic comprises mature IFN-β.

73. **(canceled)**

74. **(previously presented)** The method of claim 70, wherein the IFN-β is human IFN-β.

75. **(original)** The method of claim 74, wherein the IFN-β is at least about 95% identical to full length mature human IFN-β having SEQ ID NO: 4.

76. **(original)** The method of claim 75, wherein the IFN-β comprises SEQ ID NO: 4.

77. **(previously presented)** The method of claim 74, wherein the IFN-β is glycosylated.

78. **(canceled)**

79. **(original)** The method of claim 74, wherein the IFN-β is IFN-β-1a.

80. (original) The method of claim 74, wherein the IFN- β is IFN- β -1b.

81-84. (canceled)

85. (previously presented) The method of claim 70, wherein the IFN- β therapeutic comprises a pegylated IFN- β .

86-98. (canceled)

99. (previously presented) The method of claim 74, wherein the mammal is a human.

100-104. (canceled)

105. (withdrawn) A method for treating chronic renal failure in a mammal, comprising identifying a mammal having chronic renal failure and administering to the mammal a therapeutically effective amount of an IFN- β therapeutic.

106. (withdrawn) The method of claim 105, wherein the IFN- β therapeutic comprises mature IFN- β .

107. (canceled)

108. (withdrawn) The method of claim 105, wherein the IFN- β is human IFN- β .

109. (withdrawn) The method of claim 108, wherein the IFN- β is at least about 95% identical to full length mature human IFN- β having SEQ ID NO: 4.

110. (withdrawn) The method of claim 109, wherein the IFN- β comprises SEQ ID NO: 4.

111. (withdrawn) The method of claim 108, wherein the IFN- β is glycosylated.

112. (canceled)

113. (withdrawn) The method of claim 108, wherein the IFN- β is IFN- β -1a.

114. (withdrawn) The method of claim 108, wherein the IFN- β is IFN- β -1b.

115-118. (canceled)

119. (withdrawn) The method of claim 105, wherein the IFN- β therapeutic comprises a pegylated IFN- β .

120-132. (canceled)

133. (withdrawn) The method of claim 108, wherein the mammal is a human.

134-138. (canceled)

139. (previously presented) The method of claim 72, wherein the IFN- β is human IFN- β .

140. **(previously presented)** The method of claim 70, wherein the mammal does not harbor a hepatitis virus.
141. **(previously presented)** The method of claim 140, wherein the hepatitis virus is a hepatitis B virus.
142. **(previously presented)** The method of claim 70, wherein the glomerulonephritis was not caused by a virus.
143. **(previously presented)** A method for treating glomerulonephritis in a mammal, consisting essentially of identifying a mammal having glomerulonephritis and administering to the mammal a therapeutically effective amount of an IFN- β therapeutic.
144. **(previously presented)** The method of claim 143, wherein the IFN- β is mature human IFN- β .
145. **(previously presented)** The method of claim 70, wherein the IFN- β therapeutic is a heterologous polypeptide comprising an immunoglobulin (Ig) molecule.
146. **(previously presented)** The method of claim 70, wherein the IFN- β therapeutic comprises IFN- β fused to the constant domain of an immunoglobulin molecule.
147. **(previously presented)** The method of claim 70, further comprising determining whether at least one symptom of glomerulonephritis is alleviated.
148. **(previously presented)** The method of claim 143, further comprising determining whether at least one symptom of glomerulonephritis is alleviated.